May 5, 2025 04:07 PM EDT

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy

Zachary Brennan

Senior Editor

Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy will face an FDA advisory committee ahead of an approval decision that’s expected Aug. 31, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Bristol Myers to lay off over 500 workers in New Jersey

Recursion cuts nearly half of its pipeline, including its most advanced program

PTC's Huntington’s study succeeds, but accelerated approval uncertain

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

FDA ad­comm will re­view Capri­cor's cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Bristol Myers to lay off over 500 workers in New Jersey

Recursion cuts nearly half of its pipeline, including its most advanced program

PTC's Huntington’s study succeeds, but accelerated approval uncertain

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges